"Puerto Rico Pharmaceuticals & Healthcare Report Q1 2015" Published

The trend of pharmaceutical plant closures in Puerto Rico will lead to increasing unemployment and deterioration of the island's economy over the short term, as companies are forced to consolidate their manufacturing operations in the face of financial challenges . In the long term, Puerto Rico remains an attractive destination for medicine production, as new and renewed investments will continue to enter the country.

Headline Expenditure Projections

* Pharmaceuticals: USD3.020bn in 2013 to USD3.023bn in 2014; +0.1%. Forecast slightly down compared with Q414.
* Healthcare: USD7.76bn in 2013 to USD8.02bn in 2014; +3.4%. Forecast slightly down compared with Q414.

Full Report Details at
- http://www.fastmr.com/prod/944772_puerto_rico_pharmaceuticals_healthcare_report_q1.aspx?afid=301

Risk/Reward Index

Puerto Rico is the third most attractive pharmaceutical market in the Americas region, behind the US and Canada. Puerto Rico's Pharmaceutical Risk/Reward Index score of 63.8 out of 100 is unchanged from Q414. However, its position is threatened by improvements inBrazil, Mexico, Argentina and Colombia, given their lower operating costs and improving business environments.

Key Trends And Developments

* In December 2014, US-based Romark Laboratories said it will construct a USD110mn facility in Puerto Rico. Construction will start in January 2015 and will employ 200 people within three years.
* In December 2014, Sanofi's animal health company Merial announced it would buy a Merck manufacturing plant in Puerto Rico that was being closed and retain its 200 employees. The plant is expected to manufacture and package Heartgard and Heartgard Plus products.
* In October 2014, Eli Lilly was planning to end operations at its Guayama unit in Puerto Rico, the US. The company is seeking to divest the unit because its operations have been hampered due to patent expirations for medicines manufactured at the unit. The plant is expected to continue to operate until the end of 2015 and around 100 employees working at the unit will be offered jobs at another facility in Puerto Rico....

The Puerto Rico Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Puerto Rico Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Puerto Rico pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Puerto Rico, to test other views - a key input for successful budgeting and strategic business planning in the Puerto Rican pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q1 2015
- United Arab Emirates Pharmaceuticals & Healthcare Report Q1 2015
- Vietnam Pharmaceuticals & Healthcare Report Q1 2015
- Malaysia Pharmaceuticals & Healthcare Report Q1 2015
- Peru Pharmaceuticals & Healthcare Report Q1 2015